A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Caesalpinia bonducella

Authors

Rajpal Rajpal, Central Council for Research in Homoeopathy, New Delhi
Vinay Singh, Central Council for Research in Homoeopathy, New Delhi
V Siddiqui, Central Council for Research in Homoeopathy, New Delhi
C Nayak, Central Council for Research in Homoeopathy, New Delhi
A Majumdar, Drug Proving Research Unit of Homoeopathy, KolKata
P Chandra, Drug Proving Research Unit of Homoeopathy, KolKata
J Singh, Homoeopathic Drug Research Institute, Lucknow
S Pathak, Homoeopathic Drug Research Institute, Lucknow
G Rakshit, Drug Proving Unit (Homoeopathy), Bhubaneswar

Keywords

homoeopathy; pathogenetic effect; homoeopathic pathogenetic trial; drug proving; Caesalpinia bonducella

Article Type

Original Article

Abstract

Objective:To elicit the pathogenetic response of Caesalpinia bonducella in homoeopathic potencies on healthy human volunteers. Methodology:The drug Caesalpinia bonducella was proved by the Central Council for Research in Homoeopathy (CCRH) through randomized, double-blind, placebo-controlled design. The proving was conducted at three centres. The drug was proved in 6 & 30 centesimal potencies on 50 apparently healthy volunteers, declared eligible after their pre-trial medical examinations by the medical specialists and routine laboratory investigations. In first phase of proving, provers were given 56 doses of placebo divided in 04 doses per day for 14 days. In next two phases, 56 doses of pre-selected potencies or placebo as per the randomization were administered in divided doses same as in first phase. The symptoms manifested during the trial period were noted down by the provers and elaborated by the Proving Masters. The generated data of the drug from all three centres were compiled at provingcum- data processing cell of CCRH headquarters after de-coding. Observations:Out of 34 provers who were on actual drug trial, only 12 manifested symptoms. Drug was able to manifest symptoms in both the potencies, in more or less every part of the body. Conclusion:The pathogenetic response elicited during the proving trial, expands the scope of use of the drug Caesalpinia bonducella and will benefit the research scholars and clinicians. The generated symptoms of this drug will carry more value when verified clinically.

Digital Object Identifier

10.53945/2320-7094.1701

Publisher

Wolters Kluwer India Pvt. Ltd.

How to cite this article

Rajpal R, Singh V, Siddiqui V, et al. A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Caesalpinia bonducella. Indian J Res Homoeopathy 2012;6:8-15. doi: 10.53945/2320-7094.1701